Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and failure to disclose critical information regarding the company's Iomab-B BLA application [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Actinium's executives made false statements regarding the likelihood of FDA approval for the Iomab-B BLA, which could mislead investors [5]. Group 2: Stock Performance and Impact - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, plummeting $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [6][7]. - The decline in stock price was attributed to the market's reaction to the company's press release, which indicated regulatory challenges ahead [6]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who can adequately represent the class [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. Group 4: Additional Information and Contact - Faruqi & Faruqi encourages anyone with information regarding Actinium's conduct, including whistleblowers and former employees, to contact the firm [9].